Oragenics Announces Postponement of Annual Meeting of Shareholders
August 24 2021 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) Oragenics, Inc.
(“Oragenics” or the “Company”) today announced the Company’s
reconvened annual meeting of shareholders, on August 23, 2021 at
4:00 p.m. was adjourned due to a lack of quorum. The Company
intends to seek approval for the proposals submitted to its
shareholders at a new postponed annual meeting date when
practicable. The new annual meeting date will be established by the
Company and a new record date, will be set in conjunction
therewith; the former record date of May 5, 2021, is no longer
valid.
A quorum consists of a majority of the shares entitled to vote.
There were fewer than a majority of shares entitled to vote
present, either in person or by proxy at this meeting. The annual
meeting of shareholders therefore had no quorum and the meeting was
adjourned.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is Terra CoV-2, a
vaccine candidate to prevent COVID-19 and variants of the
SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus
spike protein research licensed from the NIH and the NRC with a
focus on addressing supply-chain challenges, and offering more
patient-friendly administration, such as intranasal. Its
lantibiotics program features a novel class of antibiotics against
infectious diseases that have developed resistance to commercial
antibiotics.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of Terra CoV-2 and lantibiotics under the timelines and
in accord with the milestones it projects; the Company’s ability to
obtain funding, non-dilutive or otherwise, for the development of
the vaccine product candidate, Terra CoV-2 and our lantibiotics,
whether through its own cash on hand, or another alternative
source; the regulatory application process, research and
development stages, and future clinical data and analysis relating
to Terra CoV-2 and lantibiotics, including any meetings, decisions
by regulatory authorities, such as the FDA and investigational
review boards, whether favorable or unfavorable; the potential
application of Terra CoV-2 to variants and other coronaviruses; the
Company’s ability to obtain, maintain and enforce necessary patent
and other intellectual property protection; the nature of
competition and development relating to COVID-19 immunization and
therapeutic treatments and demand for vaccines and antibiotics; the
Company’s expectations as to administration, manufacturing, storage
and distribution; other potential adverse impacts due to the global
COVID-19 pandemic, such as delays in regulatory review,
interruptions to manufacturers and supply chains, adverse impacts
on healthcare systems and disruption of the global economy; the
potential impact of any delisting proceedings by the NYSE for the
Company’s inability to conduct an annual meeting which could in
turn negatively affect the price and liquidity of our common stock
and impair our ability to raise capital in the future; and general
economic and market conditions and risks, as well as other
uncertainties described in our filings with the U.S. Securities and
Exchange Commission. All information set forth in this press
release is as of the date hereof. You should consider these factors
in evaluating the forward-looking statements included in this press
release and not place undue reliance on such statements. We do not
assume any obligation to publicly provide revisions or updates to
any forward-looking statements, whether as a result of new
information, future developments or otherwise, should circumstances
change, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210824005376/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com or LHA Investor
Relations Kim Golodetz 212-838-3777 kgolodetz@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024